Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00090324 |
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: quetiapine fumarate tablets |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A 6-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3b Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-Release Tablets Compared With Placebo in Adolescents With Schizophrenia (Abbreviated) |
Estimated Enrollment: | 249 |
Study Start Date: | July 2004 |
Study Completion Date: | June 2007 |
Ages Eligible for Study: | 13 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Seroquel Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D1441C00112 |
Study First Received: | August 25, 2004 |
Last Updated: | March 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00090324 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Schizophrenia |
Schizophrenia Quetiapine Tranquilizing Agents Mental Disorders Psychotropic Drugs |
Central Nervous System Depressants Psychotic Disorders Antipsychotic Agents Schizophrenia and Disorders with Psychotic Features |
Schizophrenia Quetiapine Tranquilizing Agents Mental Disorders Therapeutic Uses Physiological Effects of Drugs |
Psychotropic Drugs Central Nervous System Depressants Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions Schizophrenia and Disorders with Psychotic Features |